

***Supplemental Tables & Figures***

**Pharmacological Actions of Carbamate Insecticides at Mammalian  
Melatonin Receptors**

Grant C. Glatfelter <sup>1,2</sup>, Anthony J. Jones <sup>1</sup>, Rajendram V. Rajnarayanan <sup>3</sup>, and  
Margarita L. Dubocovich <sup>4</sup>

Department of Pharmacology & Toxicology (G.C.G., A.J.J., R.V.R., M.L.D.),  
Interdepartmental Neuroscience Program (A.J.J., M.L.D.), Jacobs School of Medicine  
and Biomedical Sciences - University at Buffalo, Buffalo, NY 14203.

Submitted to Journal of Pharmacology and experimental Therapeutics (JPET)

## 18. SUPPLEMENTAL DATA

**Supplemental Table 1.** Binding affinity values and cooperativity factors for melatonin, luzindole, and carbaryl at hMT<sub>1</sub> and hMT<sub>2</sub> melatonin receptors expressed in CHO cells.

Ligand	Ligand Competition for 2-[ <sup>125</sup> I]-Iodomelatonin Binding					
	Human MT <sub>1</sub> (A)		Human MT <sub>1</sub> (R)		Human MT <sub>2</sub> (A)	
	pK <sub>B</sub>	α	pK <sub>B</sub>	α	pK <sub>B</sub>	α
Melatonin	9.71 (9.09 - 10.3)	< 0.001	N.D.	N.D.	9.91 (9.68 - 10.2)	< 0.001
Luzindole	6.41 (6.27 - 6.56)	0.037 (0.003 - 0.093)	7.27 (7.15 - 7.39)	< 0.001	7.87 (7.65 - 8.08)	< 0.001
Carbaryl	5.43 (5.15 - 5.71)	0.017 (0.012 - 0.022)	5.36 (5.19 - 5.53)	< 0.001	6.40 (5.76 - 7.04)	< 0.001

Equilibrium binding constants ( $K_B$ ) and cooperativity factors ( $\alpha$ ) for melatonin, luzindole, and carbaryl at hMT<sub>1</sub> and hMT<sub>2</sub> melatonin receptors stably expressed in CHO cells in active (A) or resting (R) buffer (+ 100  $\mu$ M GTP, 1 mM EDTA.Na<sub>2</sub>, 150 mM NaCl), were determined by ligand competition for various concentrations (30 -1400 pM) of 2-[<sup>125</sup>I]-iodomelatonin. Radioligand concentration, IC<sub>50</sub>, and maximal fractional inhibition obtained from binding curves (see Figs. 4 and S2) were used to calculate pK<sub>B</sub> and  $\alpha$  values (Cheng and Prusoff 1973, Lazareno and Birdsall 1995). Shown are mean pK<sub>B</sub> and  $\alpha$  values with 95% confidence intervals from 3 independent experiments.  $\alpha$  < 0.01 reveals an orthosteric binding mechanism while  $\alpha \geq 0.01$  indicates allosteric binding.

**Supplemental Table 2.** 2-[<sup>125</sup>I]-iodomelatonin binding dissociation rates from hMT<sub>1</sub> and hMT<sub>2</sub> melatonin receptors in the absence and presence of luzindole or cluster 1-carbamate insecticides.

Test Compound	2-[ <sup>125</sup> I]-iodomelatonin Dissociation Binding			
	Human MT <sub>1</sub> (R)		Human MT <sub>2</sub> (R)	
	K <sub>off</sub> (min <sup>-1</sup> )	ΔK <sub>off</sub> (Veh-Test) (min <sup>-1</sup> )	K <sub>off</sub> (min <sup>-1</sup> )	ΔK <sub>off</sub> (Veh-Test) (min <sup>-1</sup> )
Vehicle	0.437 (0.366 - 0.507)	N/A	0.0827 (0.0551 - 0.110)	N/A
Luzindole	0.402 (0.358 - 0.446)	0.0345 (-0.0179 - 0.0869)	0.0890 (0.0420 - 0.136)	-0.00635 (-0.0337 - 0.0210)
Carbaryl	0.421 (0.316 - 0.527)	0.0152 (-0.0115 - 0.145)	0.0777 (0.0444 - 0.111)	0.00503 (-0.00317 - 0.132)
Fenobucarb	0.437 (0.366 - .509)	-0.0008 (-0.130 - 0.128)	0.0791 (0.0411 - 0.117)	0.00359 (-0.0120 - 0.0191)
Bendiocarb	0.447 (0.339 - 0.555)	0.0104 (-0.157 - 0.136)	0.0814 (0.0495 - 0.113)	0.00133 (-0.0109 - 0.0136)
Carbofuran	0.470 (0.356 - 0.584)	-0.0335 (-0.166 - 0.0992)	0.0796 (0.0543 - 0.105)	0.00310 (-0.0234 - 0.0296)

Dissociation rates (K<sub>off</sub>) of 2-[<sup>125</sup>I]-iodomelatonin (100 pM) binding to CHO-hMT<sub>1</sub> or CHO-hMT<sub>2</sub> membranes in resting buffer (R), initiated by challenge with 10 μM melatonin in the absence (vehicle) or the presence of 100 μM luzindole, carbaryl, fenobucarb, bendiocarb, or carbofuran (see Fig. S3). Shown are mean K<sub>off</sub> values and 95% confidence intervals of 3 independent experiments run in duplicate. Mean difference in dissociation rates (with 95% CI) between vehicle and test compounds (ΔK<sub>off</sub>) are also reported for comparison by Friedman test (MT<sub>1</sub>: *P* = 0.043; MT<sub>2</sub>: *P* = 0.74) with Dunn's post-test for multiple comparisons (*P* > 0.05 for all comparisons).

**Supplemental Table 3.** Additional information regarding descriptive statistics and analyses for Fig. 7, Fig. 8, & Fig. 9.

Figure	Post-hoc Test Comparisons (all $\alpha = 0.05$ )						<i>P</i> -value <i>P</i> =
	Control	mean $\pm$ SD	<i>n</i>	Treatment	mean $\pm$ SD	<i>n</i>	
<b>7a</b>	Total + Vehicle	97.03 $\pm$ 9.54	4	1 $\mu$ M	74.69 $\pm$ 7.83	7	<b>0.0011</b>
SCN				10 $\mu$ M	61.95 $\pm$ 8.30	7	<b>&lt; 0.0001</b>
WT	1 $\mu$ M Melatonin	28.92 $\pm$ 10.47	7	100 $\mu$ M	40.16 $\pm$ 8.83	7	<b>&lt; 0.0001</b>
<b>7b</b>	Total + Vehicle	96.12 $\pm$ 7.37	4	1 $\mu$ M	81.76 $\pm$ 11.90	7	<b>0.0821</b>
PVT				10 $\mu$ M	64.41 $\pm$ 12.00	7	<b>0.0002</b>
WT	1 $\mu$ M Melatonin	35.48 $\pm$ 9.69	7	100 $\mu$ M	45.53 $\pm$ 7.25	7	<b>&lt; 0.0001</b>
<b>7c</b>	Total + Vehicle	87.77 $\pm$ 12.25	4	1 $\mu$ M	93.58 $\pm$ 8.94	4	0.7498
PT				10 $\mu$ M	63.55 $\pm$ 7.83	4	<b>0.0127</b>
WT	1 $\mu$ M Melatonin	15.10 $\pm$ 6.51	4	100 $\mu$ M	29.21 $\pm$ 10.21	4	<b>&lt; 0.0001</b>
<b>7d</b>	Total + Vehicle	94.05 $\pm$ 1.75	2	1 $\mu$ M	83.91 $\pm$ 5.97	7	0.5403
SCN				10 $\mu$ M	62.32 $\pm$ 16.02	7	<b>0.0123</b>
<i>MT<sub>2</sub></i> KO	1 $\mu$ M Melatonin	29.87 $\pm$ 4.88	7	100 $\mu$ M	34.00 $\pm$ 14.68	7	<b>&lt; 0.0001</b>
<b>7e</b>	Total + Vehicle	100.4 $\pm$ 6.58	2	1 $\mu$ M	91.19 $\pm$ 11.74	7	0.5630
PVT				10 $\mu$ M	71.46 $\pm$ 15.91	7	<b>0.0151</b>
<i>MT<sub>2</sub></i> KO	1 $\mu$ M Melatonin	36.05 $\pm$ 8.01	7	100 $\mu$ M	43.62 $\pm$ 4.06	7	<b>&lt; 0.0001</b>
<b>7f</b>	Total + Vehicle	105.3 $\pm$ 4.97	4	1 $\mu$ M	73.19 $\pm$ 12.15	4	<b>0.0009</b>
PT				10 $\mu$ M	65.46 $\pm$ 10.51	4	<b>0.0001</b>
<i>MT<sub>2</sub></i> KO	1 $\mu$ M Melatonin	21.71 $\pm$ 1.94	4	100 $\mu$ M	40.86 $\pm$ 6.97	4	<b>&lt; 0.0001</b>
<b>8a</b>	Vehicle	2.33 $\pm$ 0.28	10	30 mins	1.77 $\pm$ 0.27	5	<b>0.0021</b>
SCN				60 mins	1.54 $\pm$ 0.25	6	<b>&lt; 0.0001</b>
				120 mins	1.88 $\pm$ 0.14	4	<b>0.0236</b>
				240 mins	2.51 $\pm$ 0.28	3	0.7196
<b>8b</b>	Vehicle	1.89 $\pm$ 0.36	10	30 mins	1.38 $\pm$ 0.44	5	0.0943
PVT				60 mins	1.46 $\pm$ 0.18	6	0.1545
				120 mins	1.71 $\pm$ 0.32	4	0.8763
				240 mins	2.59 $\pm$ 0.74	3	<b>0.0403</b>
<b>8c</b>	Vehicle	2.36 $\pm$ 0.48	3	30 mins	1.20 $\pm$ 0.51	2	0.0908
PT				60 mins	0.95 $\pm$ 0.27	2	<b>0.0439</b>
				120 mins	1.64 $\pm$ 0.42	2	0.3434
				240 mins	2.17 $\pm$ 0.51	2	0.9700
<b>9d</b>	Vehicle	0.04 $\pm$ 0.12	7	Carbaryl	0.91 $\pm$ 0.34	12	<b>&lt; 0.0001</b>
				Melatonin	1.15 $\pm$ 0.18	4	<b>&lt; 0.0001</b>

Summary table describing details of statistical analyses and descriptive statistics. Alpha set at  $P < 0.05$  for all analyses using Dunnett's post-test compared to total + vehicle (7A-F) or vehicle (8A-C, 9D). Bolded *P*-values represent significant results. Further details on statistical testing and experimental details for each figure (Fig 7, Fig. 8, Fig.9) found in corresponding figure legends or **Materials & Methods** section. Main effects and other statistical details as appropriate for each data set are reported in corresponding figure legends (Fig 7, Fig. 8, Fig.9) or **Results**.

**Supplemental Table 4.** Additional information regarding descriptive statistics and analyses for Supplemental Fig. 5 quantitative receptor autoradiography results.


Figure	Control	mean $\pm$ SD	n	Post-hoc Test Comparisons (all $\alpha = 0.05$ )				
				Treatment	Concentration	mean $\pm$ SD	n	P-value P =
<b>Supp. 5a</b> SCN WT	Total + Vehicle	101.7 $\pm$ 2.93	3	Bendiocarb	1 $\mu$ M	99.65 $\pm$ 6.49	3	0.9799
	1 $\mu$ M Melatonin	36.98 $\pm$ 2.49	3		10 $\mu$ M	89.73 $\pm$ 4.57	2	0.3245
					100 $\mu$ M	54.95 $\pm$ 13.00	3	<b>0.0005</b>
<b>Supp. 5b</b> PVT WT	Total + Vehicle	102.3 $\pm$ 3.99	3	Bendiocarb	1 $\mu$ M	109.4 $\pm$ 7.49	3	0.3274
	1 $\mu$ M Melatonin	45.14 $\pm$ 4.46	3		10 $\mu$ M	94.84 $\pm$ 0.16	2	0.3639
					100 $\mu$ M	68.52 $\pm$ 5.36	3	<b>0.0003</b>
<b>Supp. 5c</b> PT WT	Total + Vehicle	91.67 $\pm$ 6.92	2	Bendiocarb	1 $\mu$ M	84.37 $\pm$ 14.57	2	0.8540
	1 $\mu$ M Melatonin	16.34 $\pm$ 3.29	2		10 $\mu$ M	82.32 $\pm$ 11.49	2	0.7556
					100 $\mu$ M	40.32 $\pm$ 10.62	2	<b>0.0233</b>
<b>Supp. 5d</b> SCN WT	Total + Vehicle	111.8 $\pm$ 16.89	3	Fenobucarb	1 $\mu$ M	86.66 $\pm$ 18.62	3	0.9857
	1 $\mu$ M Melatonin	32.70 $\pm$ 0.88	3		10 $\mu$ M	62.32 $\pm$ 16.02	3	0.1486
					100 $\mu$ M	36.14 $\pm$ 4.95	3	<b>0.0005</b>
<b>Supp. 5e</b> PVT WT	Total + Vehicle	99.86 $\pm$ 14.84	3	Fenobucarb	1 $\mu$ M	95.22 $\pm$ 5.59	3	0.9114
	1 $\mu$ M Melatonin	31.85 $\pm$ 4.22	3		10 $\mu$ M	72.15 $\pm$ 11.06	3	<b>0.0337</b>
					100 $\mu$ M	31.82 $\pm$ 9.53	3	<b>0.0002</b>
<b>Supp. 5f</b> PT WT	Total + Vehicle	97.03 $\pm$ 15.91	2	Fenobucarb	1 $\mu$ M	59.95 $\pm$ 12.43	2	0.0598
	1 $\mu$ M Melatonin	22.86 $\pm$ 4.01	2		10 $\mu$ M	45.92 $\pm$ 2.39	2	<b>0.0210</b>
					100 $\mu$ M	23.61 $\pm$ 7.63	2	<b>0.0057</b>

Summary table describing details of statistical analyses and descriptive statistics. Alpha set at  $P < 0.05$  for all analyses using Dunnett's post-test compared to total + vehicle. Non-specific binding by melatonin is shown in each data set for reference. Bolded  $P$ -values represent significant results. Further details on statistical testing and experimental details for each figure (Supplemental Fig. 5A, B, C for bendiocarb and D, E, F for fenobucarb) found in corresponding figure legends or **Materials & Methods**. Main effects and other details as appropriate for each data set are reported in corresponding figure legends or **Results**.

**Supplemental Table 5.** Affinity constants of carbaryl for 2-[<sup>125</sup>I]-iodomelatonin binding to SCN, PVT, and PT in brain slices from C3H/HeN WT & MT<sub>2</sub>KO mice.

Genotype	Competition for 2-[ <sup>125</sup> I]-Iodomelatonin Binding		
	Mouse SCN	Mouse PVT	Mouse PT
	pK <sub>i</sub>	pK <sub>i</sub>	pK <sub>i</sub>
Carbaryl WT	5.50 (5.30 - 5.71)	5.51 (5.03 - 5.98)	5.10 (4.76 - 5.44)
Carbaryl MT <sub>2</sub> KO	5.38 (4.99 - 5.77)	5.23 (4.93 - 5.52)	5.29 (4.42 - 6.12)






Carbaryl (1-100 μM) competed for 2-[<sup>125</sup>I]-iodomelatonin (75 pM) binding to melatonin receptors in SCN, PVT, and PT C3H/HeN mouse brain slices as determined by quantitative receptor autoradiography. pK<sub>i</sub> values were calculated from K<sub>i</sub> values determined by the method of Cheng and Prusoff (1973). Shown are mean pK<sub>i</sub> values and 95% confidence intervals from *n* = 4-7 independent determinations. Values for WT mice are also appear in Table 2.




**Supplemental Figure 1. Molecular docking of carbaryl with human MT<sub>1</sub> and MT<sub>2</sub> melatonin receptor models derived from X-ray crystal structures. MT<sub>1</sub> (A; rendered in green; PDB ID: 6ME2) and MT<sub>2</sub> (B; blue; PDB ID: 6ME9) melatonin receptors in complex with ramelteon (yellow) with top 5 docked poses of carbaryl (cyan). Carbaryl**

bound to the putative MT<sub>1</sub>-melatonin binding pocket like the cognate ligand ramelteon, however at the MT<sub>2</sub>-melatonin binding pocket, carbaryl and ramelteon displayed dissimilar interactions.







**Supplemental Figure 2. Characterization of 2-[<sup>125</sup>I]-iodomelatonin binding mechanism for melatonin and luzindole.** The ordinates represent 2-[<sup>125</sup>I]-iodomelatonin binding expressed as percent total 2-[<sup>125</sup>I]-iodomelatonin binding to membranes from CHO cells stably expressing hMT<sub>1</sub> (A,C,E) or hMT<sub>2</sub> (B,D) melatonin receptors. Membranes were incubated with 2-[<sup>125</sup>I]-iodomelatonin (■ = 30 pM, △ = 100 pM, ▼ = 300 pM, ◇ = 600 pM, ● = 1000 pM, ▲ = 1400) and control, melatonin (A,B; 10 pM – 1 μM) or luzindole (C-E; 1 nM-100 μM) in active (A-D) and resting buffer (E; + 100 μM GTP, 1 mM EDTA.Na<sub>2</sub>, 150 mM NaCl). Points shown are the mean from representative experiments independently repeated three times. See Table S1 for derived binding constants (K<sub>B</sub>) and cooperativity factors (α; α < 0.01, orthosteric; α ≥ 0.01, allosteric).



**Supplemental Figure 3. Cluster 1-carbamate insecticides likely bind to melatonin receptor orthosteric sites.** 2-[<sup>125</sup>I]-iodomelatonin (100 pM) binding to CHO-hMT<sub>1</sub> (A,C) or CHO-hMT<sub>2</sub> (B,D) membranes, in resting buffer (100 μM GTP, 1 mM EDTA.Na<sub>2</sub>, 150 mM NaCl), is allowed to reach equilibrium and dissociation is initiated by challenge with 10 μM melatonin in the absence or the presence of 100 μM luzindole (LUZ), carbaryl (CBRL), fenobucarb (FNBC), bendiocarb (BNDC), or carbofuran (CBFN). (A,B) The ordinate represents 2-[<sup>125</sup>I]-iodomelatonin binding expressed as percent total 2-[<sup>125</sup>I]-iodomelatonin binding and the abscissa represents time after concurrent addition of melatonin and test compound. Symbols shown are the mean from three independent experiments, each run in duplicates. (C,D) Symbols on the left panels are means of K<sub>off</sub> from technical replicates run in duplicate while bars represent the mean of these values (n = 3). Symbols on the right panels indicate the difference (Δ) in 2-[<sup>125</sup>I]-iodomelatonin K<sub>off</sub> for individually paired determinations with vehicle or test compounds. The mean ΔK<sub>off</sub> and 95% confidence intervals are reported on the right as well. See Table S2 for dissociation rates. K<sub>off</sub> values with test compounds are compared to vehicle using a Friedman test (A: *P* = 0.043; B: *P* = 0.74) with Dunn's post-test for multiple comparisons (*P* > 0.05 for all comparisons).



**Supplemental Figure 4. Carbamate insecticides compete for 2-[<sup>125</sup>I]-iodomelatonin binding to hMT<sub>1</sub> and hMT<sub>2</sub> melatonin receptors without and with G protein inactivation: Representative Curves.** The ordinate represents 2-[<sup>125</sup>I]-iodomelatonin binding expressed as percent total binding. Membranes from CHO cells stably expressing hMT<sub>1</sub> (A,C,E,G, ■ for control, □ for 100 μM GTP) or hMT<sub>2</sub> (B,D,F,H, ◆ for control, ◇ for 100 μM GTP) melatonin receptors were incubated with 2-[<sup>125</sup>I]-iodomelatonin (75 pM) in the absence (○) and the presence of various concentrations of melatonin (A,B), luzindole (C,D), fenobucarb (E,F) or bendiocarb (G,H). Points shown are the mean from representative experiments independently repeated at least three times. See Table 3 for derived affinity constants.



**Supplemental Figure 5. Quantitative receptor autoradiography demonstrates bendiocarb and fenobucarb competes *in-vitro* for 2-[<sup>125</sup>I]-iodomelatonin binding at**

**melatonin receptors in slices containing the SCN, PVT, and PT from C3H/HeN**

**mice.** (A-F) Optical densities obtained for each treatment are normalized to proportion total binding in the absence of drug treatment (bendiocarb A-C, fenobucarb D-F) for each animal. Brain slices were treated with vehicle or drug (1, 10, 100  $\mu\text{M}$ ) in vehicle during a 1-hour incubation to determine competition for 2-[ $^{125}\text{I}$ ]-iodomelatonin binding (75 pM) at melatonin receptors in slices containing the SCN, PVT, and PT. Dotted lines in each panel represent non-specific binding for adjacent slices treated with 1  $\mu\text{M}$  melatonin for each data set. Values ( $n = 2-3$ ) in each panel are compared to % total binding of vehicle using a one-way ANOVA with Dunnett's post-test ( $P < 0.05$ ). \* $P < 0.05$ ; \*\* $P < 0.01$ ; \*\*\* $P < 0.001$ . See Table 2 for derived affinity constants. See Supplemental Table 4 for additional information regarding descriptive statistics and data comparisons.